Publications by authors named "Rubi Li"

Claim this Profile
T
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
David Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, Rubi Li, Diego Cortinovis

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study.
Momoko Tokura, Mark Malalay Ando, Yuki Kojima, Rui Kitadai, Shu Yazaki, Rubi K Li, Manuelito A Madrid

Breast Cancer (Auckl)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Jessa Gilda P Pandy, Paula Isabel G Franco, Rubi K Li

Support Care Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma.
Sylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, Sébastien Carrère, Anne Ducassou, Marco Rastrelli, Rubi K Li

Int J Radiat Oncol Biol Phys· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.
Rubi K Li, Eriko Tokunaga, Hryhoriy Adamchuk, Vladimir Vladimirov, Eduardo Yanez, Alicia Vana, Oleg Lipatov

BioDrugs· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Justin Stebbing, Yauheni V Baranau, Valery Baryash, Alexey Manikhas, Vladimir Moiseyenko, Dmytro Boliukh, Rubi K Li

Breast Cancer Res Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Gee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, Yuh-Min Chen, Jin-Yuan Shih, Rubi Li, Darren Wan-Teck Lim, Philippe Carriere

Int J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Sylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, Sébastien Carrère, Anne Ducassou, Marco Rastrelli, Rubi K Li, Philippe Terrier

Lancet Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Mark D Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, Sachin Hingmire, Hirotaka Iwase, Rubi K Li, Ray Li, Alicia Vana, Elizabeth Tan-Chiu

Br J Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Justin Stebbing, Yauheni Baranau, Valeriy Baryash, Alexey Manikhas, Vladimir Moiseyenko, Dmytro Boliukh, Rubi K Li

Lancet Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
Brian Leyland-Jones, Igor Bondarenko, Gia Nemsadze, Vitaliy Smirnov, Iryna Litvin, Irakli Kokhreidze, Lia Abshilava, Mikheil Janjalia, Rubi Li, Liang Xiu

J Clin Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
Se-Hoon Lee, Yung-Jue Bang, Paul Mainwaring, Christina Ng, John W-C Chang, Philip Kwong, Rubi K Li

Asia Pac J Clin Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Linda T Vahdat, Eduard Vrdoljak, Henry Gómez, Rubi Khaw Li, Linda Bosserman

J Geriatr Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
Vicente Valero, Eduard Vrdoljak, Binghe Xu, Eva Thomas, Henry Gómez, Rubi Khaw Li, Linda Bosserman, Linda Vahdat

Clin Breast Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Gabriel N Hortobagyi, Henry L Gomez, Rubi K Li, Hyun-Cheol Chung, Luis E Fein, Linda T Vahdat

Breast Cancer Res Treat· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A study of phonon vibration like modes for aggregation structure in silicate melts by high temperature Raman spectrum].
Pei-Cang Xu, Ru-Bi Li, Tong-Ming Shang, Jian Zhou, Jian-Hua Sun, Jing-Lin You

Guang Pu Xue Yu Guang Pu Fen Xi· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Xavier B Pivot, Rubi K Li, Eva S Thomas, Hyun-Cheol Chung, Luis E Fein

Eur J Cancer· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Eva S Thomas, Henry L Gomez, Rubi K Li, Hyun-Cheol Chung, Luis E Fein, Judith V Klimovsky, Linda T Vahdat

J Clin Oncol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis